CME: Addressing unmet needs and appreciating the place of vaccination in the prevention of human papillomavirus (HPV) infection
ACCREDITATION EXPIRED: December 21, 2024
Activity Description / Statement of Need:
In this online, self-learning activity:
The term human papillomavirus encompasses a family of DNA viruses that are sexually transmittable and may cause either benign or malignant lesions. They are the leading cause of cervical cancer (CC), with approximately 90% of CC cases attributable to HPV, as well as a major contributor to anogenital and head and neck cancers, although many patients infected with HPV will never develop any related symptoms or disease. The prevalence of HPV in the U.S. is 42.5 million people, and direct medical costs attributed to it are $775 million. HPV 16 accounts for a majority or plurality of HPV-related cancers of both genital tract and head and neck.
The CDC’s Advisory Committee on Immunization Practices (ACIP) recommends HPV vaccination beginning as early as age nine for both sexes, with the schedule and number of doses dependent on age of first dose.
Target Audience:
The following HCPs: Primary care physicians and pediatricians; physician assistants, nurse practitioners, and pharmacists who practice in the aforementioned areas of specialty; and any other HCPs with an interest in or who clinically encounter patients who would benefit from HPV vaccination.
Commercial Support Disclosure: This program is supported by an educational grant from Merck.
This activity is free of charge.
Release Date: December 21, 2022 -- Expiration Date: December 21, 2024
Faculty: Maureen Killackey, MD
Agenda
|
Faculty introduction, disclosures |
|
Introductory content and review of HPV
|
|
HPV vaccination
|
|
Summary, conclusions, and best practice recap |
Learning Objectives
By the end of the session the participant will be able to:
- Describe the healthcare burden associated with HPV infection and the importance of HPV vaccination.
- Summarize the safety and efficacy of HPV vaccination and the recommended schedules and appropriateness of the vaccine for different patient populations.
- Recall challenges to HPV vaccination.
- Formulate a plan to address concerns about and objections to HPV vaccination by patients and parents.
Accreditation
ACCME Activity #202370036
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.Faculty Disclosure and Resolution of COI
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.
Disclosure of Faculty: Maureen Killackey, MD, FACS, FACOG, Former Professor, Medicine and Professor, Obstetrics and Gynecology, Columbia University Medical Center has received financial compensation for consulting work from Exact Sciences.
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.
Faculty will NOT discuss off-label uses.
All relevant financial relationships have been mitigated.
ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Commercial Support Disclosure: This program is supported by an educational grant from Merck.
Instructions
- Read the learning objectives above
- Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
- View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
- Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
- Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.
System Requirements
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Additional Courses That Are Related To This Activity
Prediction and management of bone complications in prostate cancer
Preventing and mitigating skeletal-related events in breast cancer
Primary immunodeficiency disorders (PIDD): Present management and ongoing needs